NL
DNA icon

NKCFO LLC’s Ginkgo Bioworks DNA Stock Holding History

NKCFO LLC’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149K Buy
+15,000
New +$125K 0.05% 73

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

NKCFO LLC's DNA Position: Q2 2026 in Review

NKCFO LLC opened a new position in Ginkgo Bioworks (DNA) in Q2 2026: 15,000 shares worth $149K. The stake represents 0.05% of the portfolio and ranks #73 among its holdings.

184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • NKCFO LLC held 15,000 shares of Ginkgo Bioworks worth $149K as of Q2 2026.
  • Ginkgo Bioworks was a new NKCFO LLC position in Q2 2026.
  • Ginkgo Bioworks made up 0.05% of NKCFO LLC's portfolio in Q2 2026, its #73 holding.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on NKCFO LLC's 13F filing for Q2 2026, filed 13 Aug 2026.